Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2014 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (210)	1/17/2014 8:28:44 PM
From: guerlain	Read Replies (1) \| Respond to of 487

Thanks for the update, BulbaMan! Ouch, am I the only one that my contest portfolio outperforms my real-life portfolio by significant margin...

To: BulbaMan who wrote (210)	1/17/2014 10:30:14 PM
From: Clarksterh	Respond to of 487

At Friday’s close the Contest median was up a phenomenal 19.22% YTD (vs. 13.58% YTD a week ago), stomping the Nasdaq Biotech Index’s 9.15% YTD gain (vs. 5.15% YTD a week ago). This week is the week of Innate+RTRX. Most of the people in the top 10 had both - often with one or the other at 20%. With those two removed from everyone's portfolio we'd undoubtedly be a lot closer to the Nasdaq Biotech Index.

To: BulbaMan who wrote (210)	1/24/2014 5:22:06 PM
From: BulbaMan	Read Replies (5) \| Respond to of 487

1/24/14 Contest update Science magazine dubbed “immunotherapy” the breakthrough of the year and it may well turn out to be the assassin of the “Emperor of all Maladies.” Early in the week, there was also hope biotech stocks had become immune from a serious correction. But, by Friday, such hope was dashed as biotechs plunged together with the overall market. Still, at Friday’s close, the Contest median was up a remarkable 17.54% YTD (vs. up 19.22% YTD a week ago), while the Nasdaq Biotech Index finished the week with a 7.64% YTD gain (vs. up 9.15% YTD a week ago). Meanwhile, the Nasdaq Composite Index fell to negative territory, closing down -1.16% YTD (vs. up .50% YTD a week ago). One need not look further than my own Contest portfolio to see how crazy biotech stocks have been. Capricor, my zodiac killer of a stock, has thrust my portfolio to first place with a mind-boggling 54.17% YTD gain! ROCKY’s portfolio, up 29.98% YTD, moved into second place and just a smidgen behind, JB118's portfolio dropped to third place with a 29.88% YTD gain . At Friday's close, all 46 Contest portfolios remained in the black and 45 of the 46 contestants continued to beat the NBI. Below is the Top Ten list. Also below are the Top 5 & Bottom 5 Stocks ranked by % Gained and % Lost for the week. Portfolio adjustments: none (All corrections, especially adjustments for splits, greatly appreciated.) Have a safe & relaxing weekend biotechies! Peace & good health, Bulba 1/24/14 Rank Name Profit/Loss 1 BULBA 54,173 2 ROCKY 29,977 3 JB118 29,879 4 BTH2013 28,882 5 GUERL 28,236 6 MCBIO 27,029 7 SCARAM 26,696 8 DOUGH 26,595 9 MOPGCW 26,589 10 RKRW 26,236 Week's Top 5 Gainers Symbol 1/17 1/24 Wk.%chg. CAPR 9.30 14.70 58.06% ARIA 6.90 8.99 30.29% PRAN 7.10 8.99 26.62% GERN 4.51 5.62 24.75% AMF.TO 0.35 0.40 15.94% Week's Worst 5 Losers Symbol 1/17 1/24 Wk.%chg. AMRN 2.27 1.710 -24.67% AGIO 35.93 28.340 -21.12% RTRX 13.10 10.430 -20.38% GALE 7.00 5.700 -18.57% ONVO 11.15 9.120 -18.21%